Wugen Announces Data Presentation at The Society for Immunotherapy of Cancer’s (SITC) 36th Annual Meeting

ST. LOUIS & SAN DIEGO–(BUSINESS WIRE)–Wugen, Inc., a clinical-stage biotechnology company developing a pipeline of off-the-shelf memory natural killer (NK) cell therapies to treat a broad range of hematological and solid tumor malignancies, today announced it will present new data highlighting the preclinical development of Wugen’s lead product WU-NK-101 at the Society for Immunotherapy of Cancer’s (SITC) 36th Annual Meeting. The data highlight Wugen’s proprietary large-scale feeder-cell free
Click here to view original post